Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., Oct. 27, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech developing a novel treatment for...
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company")...
JOY GROUP Completes Acquisition of Italian Dermatological Hair Care Brand Foltène
SHANGHAI, Oct. 21, 2025 /PRNewswire/ -- China's leading multi-brand beauty group JOY GROUP (Shanghai Juyi Cosmetics Co., Ltd.) has announced the completion of its acquisition of Foltene, a dermatological hair care brand from Italy. Products of...
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of s mall m olecule GLP-1 receptor ( GLP-1R) a gonist ASC30 in 65 participants...
ALR Technologies Completes Definitive Manufacturing Agreement for GluCurve Pet CGM
SINGAPORE, June 25, 2025 /PRNewswire/ -- ALR Technologies SG Ltd. ("ALRT" or the "Company") (OTCPK: ALRTF), the diabetes management company, announces it has entered into a Definitive Manufacturing Agreement with CGM Medical Technology Shen Zhen...
Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations
SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus platinum-based...
ShawKwei & Partners Completes Acquisition and Delisting of PEC Ltd
SINGAPORE, June 19, 2025 /PRNewswire/ -- ShawKwei & Partners ("ShawKwei"), an Asian private equity industrial investor, has completed the US$165 million acquisition and final delisting of PEC Ltd ("PEC") from the Singapore Exchange. The PEC...
United Risk Completes Acquisition of Pinnacle Underwriting Based in Sydney, Australia Expanding and Strengthening Operations in the Asia-Pacific and Middle East Regions in Key Lines of Business
Specialty facultative reinsurance MGA bolsters United Risk's business, among the largest in the world and now unique for its diversified scale and geographic reach NEW YORK, June 18, 2025 /PRNewswire/ -- Mr. Hayden Smith, United Risk's Regional CEO...
Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
SHANGHAI, June 16, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4...
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the...